ReviewFrontiers in oncology2023
Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Treatment-induced ripple effect: a systematic review exploring the abscopal phenomenon in Glioblastoma multiforme.Journal of neuro-oncology · 2025Pooled it
- Gamma knife radiosurgery for cerebellar brain metastases: clinical outcomes and artificial intelligence-based predictive modeling.Clinical & experimental metastasis · 2026Article
- Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene-negative NSCLC with brain metastases: a real-world IPTW analysis.Frontiers in immunology · 2026Article
- Assessment of real-world surveillance strategies for patients undergoing systemic therapy for brain metastases.Frontiers in oncology · 2026Article
- Stereotactic radiosurgery for patients with brain metastases from nasopharyngeal carcinoma.Journal of neuro-oncology · 2025Article
- Global Growth and Distribution of CyberKnife Stereotactic Radiosurgery: A Bibliometric Analysis.Neurosurgery practice · 2025Review
- New Approaches in Radiotherapy.Cancers · 2025Review
- Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.Nature reviews. Clinical oncology · 2025Review
- Current Treatment Paradigms for Advanced Melanoma with Brain Metastases.International journal of molecular sciences · 2025Review
- The Role of CyberKnife Stereotactic Radiosurgery in Recurrent Cranial Medulloblastomas across Pediatric and Adult Populations.Journal of clinical medicine · 2024Article
- Survival after Stereotactic Radiosurgery in the Era of Targeted Therapy: Number of Metastases No Longer Matters.Current oncology (Toronto, Ont.) · 2024Article
- Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma.Cancers · 2024Review
- Should we be afraid of radiotherapy for hemorrhagic brain metastases? A narrative review.Therapeutic advances in medical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid tumors metastasizing to the brain are a frequent occurrence with an estimated incidence of approximately 30% of all cases. The longstanding conventional standard of care comprises surgical resection and whole-brain radiotherapy (WBRT); however, this approach is associated with limited long-term survival and local control outcomes. Consequently, stereotactic radiosurgery (SRS) has emerged as a potential alternative approach. The primary aim of SRS has been to improve long-term control rates. Nevertheless, rare observations of abscopal or out-of-field effects have sparked interest in the potential to elicit antitumor immunity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.